ArticleMolecular informatics2026
To What Extent Can We Extrapolate Proteochemometric Models: A Case Study for the SLC6 Transporter Family.
Article in Molecular informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Proteochemometrics (PCM) modeling combines protein and ligand information to create predictive models for biological activity. It aims to extrapolate information across targets, enabling its application in screening drug candidates across a whole family of proteins. In this study, we investigate the ability of PCM models to extrapolate information from data-rich proteins to data-poor ones and present a series of PCM models for the SLC6 transporter family showing reasonable performance (Q2 values up to 0.79). Moreover, feature importance analysis pointed towards residue position A173 in hSERT, corresponding to G149 and G153 in hNET and hDAT, respectively, to be relevant for subtype selectivity. However, examining the impact of different data splits on model validation metrics highlights potential over-optimism when only considering target stratification splits. Target stratification split only maintains the train/test ratio across all targets, preserving per target balance without considering chemical similarity. However, when performing leave-one-transporter-out studies, a considerable drop in performance was observed. This points towards the need for more complex technologies to exploit the potential of PCM and identify new drug candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.